Abstract:Proc Amer Assoc Cancer Res, Volume 45, 2004 2477 The MAP kinase pathway transmits proliferative signals for a number of growth factors and receptors and plays a central role in the growth of many human cancers. MEK (MAP kinase kinase), a central player in the Ras-MAP kinase pathway, is a critical signaling protein for multiple oncogenic pathways including the ErbB family, VEGF, PDGF, and mutated ras. MEK inhibitors therefore have the potential for a broader spectrum of antitumor activity than agents that inhibit only one portion of a tumor’s redundant proliferative pathways. We have previously described the identification and evaluation of PD 184352 (CI-1040), the first MEK inhibitor reported to modulate phosphorylation of MAP kinase in tumor-bearing animals (Sebolt-Leopold et al, Nature Medicine, 5, 810-816, 1999). CI-1040 was well tolerated in Phase 1 studies and did modulate tumor pERK levels at tolerated doses, although low overall bioavailability of the drug hampered its further development. To increase the bioavailability of CI-1040, we have explored the incorporation of polar, solubilizing substituents into the CI-1040 template. In this presentation, we describe synthesis and structure-activity-relationships (SAR) of a new class of N-aryl anthranilic acid hydroxamates that has led to PD 0325901. A variety of functionalized hydroxamate esters were surveyed and maximal in vitro potency was obtained by the incorporation of hydroxyalkyl esters. Further optimization of three sites on the CI-1040 ring system provided an additional boost in potency. These new sub-nanomolar inhibitors, display exquisite selectivity for MEK, like CI-1040. A recently obtained co-crystal structure of a MEK1 construct with PD 0318088, a PD 0325901 congener, explains the kinase selectivity of Pfizer’s MEK inhibitors and is highlighted here.

2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)

Synthesis and SAR Development of PD 0325901, a Potent and Highly Bioavailable MEK Inhibitor.

Discovery of Coumarin-Based MEK1/2 PROTAC Effective in Human Cancer Cells.

Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader.

Discovery of Carbazole Derivatives As Novel Allosteric MEK Inhibitors by Pharmacophore Modeling and Virtual Screening

Allosteric Modulators of MEK1: Drug design and Discovery.

Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).

Structure-based design and synthesis of 5-benzyl-2-phenylpyrimidin-4(3H)-one derivatives as novel MEK1 inhibitors

Allosteric Modulators of MEK1: Drug Design and Discovery

Optically Activated MEK1/2 Inhibitors (Opti-Meki) As Potential Antimelanoma Agents

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-Met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(quinolin-6-ylmethyl)-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1h-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment Of

Synthesis and biological evaluations of 3-benzothiazol-2-yl coumarin derivatives as MEK1 inhibitors

Synthesis and biological evaluation of novel N -(piperazin-1-yl)alkyl-1 H -dibenzo[ a , c ]carbazole derivatives of dehydroabietic acid as potential MEK inhibitors.

Lessons from (S)-6-(1-(6-(1-methyl-1h-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase C-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats

Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer

Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Design, Synthesis, and Biological Evaluation of 5-Amino-4-fluoro-1 H -benzo[ d ]imidazole-6-carboxamide Derivatives as Novel and Potential MEK/RAF Complex Inhibitors Based on the "Clamp" Strategy

Non-oxime inhibitors of B-Raf(V600E) kinase

Analysis of the ERK Pathway Cysteinome for Targeted Covalent Inhibition of RAF and MEK Kinases

Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders